Search research articles
Contact Us
Filters
Showing results (51-60 of 173) with videos related to
Page
of 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 9, 2011
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study
Ana Oaknin, Desamparado Roda, Antonio González-Martín, et al.
Cancers
|
February 25, 2022
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Andres Poveda, Raquel Lopez-Reig, Ana Oaknin, et al.
Future Oncology (London, England)
|
August 24, 2021
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer
Ana Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Gynecologic Oncology
|
June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F Liu, Michael Gordon, Jennifer Veneris, et al.
The New England Journal of Medicine
|
February 21, 2014
Improved survival with bevacizumab in advanced cervical cancer
Krishnansu S Tewari, Michael W Sill, Harry J Long, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
Robert L Coleman, Domenica Lorusso, Ana Oaknin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2024
Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Ester Bonfill-Teixidor, Almudena Neva-Alejo, Alexandra Arias, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M William Audeh, James Carmichael, Richard T Penson, et al.
British Journal of Cancer
|
July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
Rebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2023
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
Nicoletta Colombo, Toon Van Gorp, Ursula A Matulonis, et al.
Page
of 18
Search research articles
Search
Showing results (51-60 of 173) with videos related to
Sort By:
Page
of 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 9, 2011
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study
Ana Oaknin, Desamparado Roda, Antonio González-Martín, et al.
Cancers
|
February 25, 2022
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Andres Poveda, Raquel Lopez-Reig, Ana Oaknin, et al.
Future Oncology (London, England)
|
August 24, 2021
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer
Ana Oaknin, Anna V Tinker, Lucy Gilbert, et al.
Gynecologic Oncology
|
June 18, 2019
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F Liu, Michael Gordon, Jennifer Veneris, et al.
The New England Journal of Medicine
|
February 21, 2014
Improved survival with bevacizumab in advanced cervical cancer
Krishnansu S Tewari, Michael W Sill, Harry J Long, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
Robert L Coleman, Domenica Lorusso, Ana Oaknin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 30, 2024
Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Ester Bonfill-Teixidor, Almudena Neva-Alejo, Alexandra Arias, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M William Audeh, James Carmichael, Richard T Penson, et al.
British Journal of Cancer
|
July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
Rebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2023
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
Nicoletta Colombo, Toon Van Gorp, Ursula A Matulonis, et al.
Page
of 18